Загрузка...
Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in-human, first-in class, orally bio-available Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the Un...
Сохранить в:
| Опубликовано в: : | J Exp Pharmacol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863308/ https://ncbi.nlm.nih.gov/pubmed/27186122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S26591 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|